Publications by authors named "Steve D Pratt"

Claim this Profile
I
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Adrian D Hobson, Russell A Judge, Ana L Aguirre, Brian S Brown, Yifang Cui, Steve D Pratt

J Med Chem· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
Russell A Judge, Anil Vasudevan, Victoria E Scott, Gricelda H Simler, Steve D Pratt

Chembiochem· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery of a potent NAMPT inhibitor.
Alla Korepanova, Kenton L Longenecker, Steve D Pratt, Sanjay C Panchal, Richard F Clark

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compounds.
Vivek C Abraham, Loan N Miller, Steve D Pratt, Brent Putman, Laura Kim

Eur J Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists.
Jun Chen, Marc R Lake, Reza S Sabet, Wende Niforatos, Steve D Pratt

J Biomol Screen· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antibacterial class: a series of tetracyclic derivatives.
Mira M Hinman, Teresa A Rosenberg, Darlene Balli, Candace Black-Schaefer, Linda E Chovan, Steve D Pratt

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants.
Richard F Clark, Sanyi Wang, Zhenkun Ma, Moshe Weitzberg, Christopher Motter, Steve D Pratt

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antibacterial class.
Peter J Dandliker, Steve D Pratt, Angela M Nilius, Candace Black-Schaefer, Xiaoan Ruan

Antimicrob Agents Chemother· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis